Physician profile
Imran Akram
NPI 1053449389
$660.34
in general payments reported to CMS, 2019-2025
9 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.36 · 2022: $19.48 · 2023: $211 · 2024: $223 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553 · Education: $54.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.96 |
| Education | $54.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $168.52 | 2023-2024 | Uzedy |
| Otsuka America Pharmaceutical, INC. | $134.37 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $124.18 | 2019-2024 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $81.21 | 2025 | Cobenfy |
| Alkermes, INC. | $42.00 | 2023 | Lybalvi, Vivitrol |
| Indivior INC. | $40.87 | 2024 | Sublocade |
| Braeburn INC. | $26.19 | 2025 | Brixadi |
| Axsome Therapeutics, INC. | $23.52 | 2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $19.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Akram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.